Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib in pediatric fibrosing interstitial lung disease (InPedILD-ON)
NCT05285982Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2022
- Primary completion
- Aug 2025
- Countries
- 17
01
Overview
A Phase 3 trial of nintedanib in interstitial lung disease (ILD), sponsored by Boehringer Ingelheim. Started Apr 2022; status: completed.
02
Drugs
nintedanib
03
Conditions
interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT05285982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05285982.